After inking major deals with AbbVie and AstraZeneca, China-US company Harbour BioMed recently shifted strategy, divesting its site in Suzhou to WuXi in a bid to be “more focused, efficient and nimble” and emerge stronger post-pandemic, says founder, chairman and CEO Jingsong Wang in an exclusive interview.

US-listed Chinese biotechs are switching auditors in hopes of satisfying the US securities regulator's demands - but legal experts also see other considerations at play.

The latest move signals a toughening stance in China over sensitive technology exports, as the bilateral relationship with the US continues its free fall.

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.